Age, Biography and Wiki
David Tuveson was born on 1 January, 1966 in United States, is an American cancer biologist (born 1966). Discover David Tuveson's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is he in this year and how he spends money? Also learn how he earned most of networth at the age of 58 years old?
| Popular As |
N/A |
| Occupation |
N/A |
| Age |
58 years old |
| Zodiac Sign |
Capricorn |
| Born |
1 January, 1966 |
| Birthday |
1 January |
| Birthplace |
N/A |
| Nationality |
United States
|
We recommend you to check the complete list of Famous People born on 1 January.
He is a member of famous with the age 58 years old group.
David Tuveson Height, Weight & Measurements
At 58 years old, David Tuveson height not available right now. We will update David Tuveson's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
| Physical Status |
| Height |
Not Available |
| Weight |
Not Available |
| Body Measurements |
Not Available |
| Eye Color |
Not Available |
| Hair Color |
Not Available |
Dating & Relationship status
He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.
| Family |
| Parents |
Not Available |
| Wife |
Not Available |
| Sibling |
Not Available |
| Children |
Not Available |
David Tuveson Net Worth
His net worth has been growing significantly in 2023-2024. So, how much is David Tuveson worth at the age of 58 years old? David Tuveson’s income source is mostly from being a successful . He is from United States. We have estimated David Tuveson's net worth, money, salary, income, and assets.
| Net Worth in 2024 |
$1 Million - $5 Million |
| Salary in 2024 |
Under Review |
| Net Worth in 2023 |
Pending |
| Salary in 2023 |
Under Review |
| House |
Not Available |
| Cars |
Not Available |
| Source of Income |
|
David Tuveson Social Network
Timeline
David Arthur Tuveson (born January 1, 1966) is an American cancer biologist and is currently Roy J. Zuckerberg Professor of Cancer Research as well as The Cancer Center Director at Cold Spring Harbor Laboratory.
Dr. Tuveson is also the Chief Scientist for the Lustgarten Foundation for Pancreatic Cancer Research.
He is known for developing some of the first mouse models of pancreatic cancer and more recently, for his work developing pancreatic cancer organoids.
David Tuveson received a B.S. in chemistry from the Massachusetts Institute of Technology in 1987.
He received an M.D. and Ph.D. from the Johns Hopkins School of Medicine in 1994, where his Ph.D. adviser was Douglas Fearon.
He completed a residency at Brigham and Women's Hospital from 1994-1997.
From 1997-2000, he pursued a Fellowship in Hematology and Oncology at the Dana–Farber Cancer Institute.
During this time, he also performed postdoctoral research in mouse models of lung cancer in the laboratory of Tyler Jacks at the Massachusetts Institute of Technology.
Following completion of his fellowship training, Tuveson started his own laboratory at the University of Pennsylvania, where he was an assistant professor of medicine from 2002 to 2006.
David Tuveson was given an AACR-PanCAN Career Development Award in Pancreatic Cancer research in 2003.
He was also the recipient of an M.L. Smith Award in 2003, a Rita Allen Foundation Scholar Award in 2004, and a Distinguished Scholar Award from the Lustgarten Foundation.
In 2006, he moved to the Cambridge Research Institute, where he was a senior group leader and a professor of pancreatic cancer medicine.
In 2012, he took a position as a group leader and the deputy director of the Cancer Center at Cold Spring Harbor Laboratory.
In 2016, Tuveson assumed the position of Director of the Cold Spring Harbor Laboratory Cancer Center.
He served as the President for the American Association for Cancer Research from 2021 to 2022.
He is a member of the editorial board for Oncogene, Journal of Experimental Medicine, and Cancer Discovery (journal).
He also serves on the scientific advisory board for Leap Therapeutics and the Board of Scientific Advisors for the National Cancer Institute.
He was awarded Hamdan Award for Medical Research Excellence - Pancreatic Diseases by Hamdan Medical Award in 2016.
He received a 2022 Luminary Award and was on Clarivate’s list of the top most cited researchers in 2022.
Tuveson has an h-index of 102 according to Google Scholar.
Some of his most important publications are:
In 2017, he partnered with the National Cancer Institute to develop organoids for use more broadly by the cancer research community.
In 2020, Tuveson was elected as Fellow of the American Association for Cancer Research, and in 2022, he was elected to the National Academy of Medicine.
He also co-founded the biotechnology company Mestag Therapeutics in 2021.
During his postdoctoral training in the Jacks Laboratory, Tuveson learned how to engineer mouse models to study human cancer.
During this time, he also studied gastrointestinal stromal tumors (GISTs), and worked with Dr. George Demetri to develop imatinib as a treatment for GIST.
When he started his own laboratory at the University of Pennsylvania, Tuveson developed some of the first genetically engineered mouse models to aid in the study of pancreatic cancer.
Using these mice, Tuveson has made several important discoveries in the biology of pancreatic cancer, including the work that contributed to the idea that the stromal cells of pancreatic tumors act as a barrier for therapies.
He later partnered with Hans Clevers to develop pancreatic cancer organoids – tumor cells taken from a human patient and cultured in the laboratory as three-dimensional spheres.
